Shots:

• Health Canada- under (NOC/c) policy- has granted market authorization to Polivy + bendamustine and rituximab (BR) for six 21-day cycles in adult patients with r/r DLBCL- who are not eligible for ASCT and prior treated with at least one therapy
• The approval is based on P-I/II GO29365 study assessing Polivy + BR vs BR alone in 80 patients- including 4 Canadians with previously treated DLBCL.  Results: patients achieving CR or PR (40% vs 18%); mDoR (12.6 vs 7.7mos.)
• Polivy is an ADC- targeting CD79b and destroys the B cells through the delivery of an anti-cancer agent- while minimizing the effects on normal cells

­ Ref: PRNewswire | Image: Roche